Breast Cancer Foundation NZ
Cyclox II
Advanced Breast Cancer clinical trials for ER+
Recruiting
Updated: January 20, 2022
This study is comparing capecitabine with capecitabine and oral cyclophosphamide in patients with advanced breast cancer.
This study is comparing capecitabine with capecitabine and oral cyclophosphamide in patients with advanced breast cancer.
Key inclusion criteria
- Histological or cytological evidence of breast carcinoma with at least one of the following: distant metastases, T4 or N2 or N3, or local recurrence following mastectomy; measurable disease; treatment with palliative intent; performance status 0-3 (WHO); aequate bone marrow, renal and liver function and creatinine clearance > 50ml/min.
Key exclusion criteria
- Male; less than six months since last dose of adjuvant chemotherapy; more than one prior regimen for advanced disease; pregnant or breast feeding; concurrent anticancer therapy; other malignancy within 5 years except adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix.
New Zealand
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.